BRAF and melanoma: Factor 12 also related to phenotypic measurements that are typical of melanomas, correlating with CRISPR-Cas9 gene essentiality scores for BRAF (Figure 3C) and with its inhibitor, dabrafenib (Figure 3D), both of which are strongly associated with cell lines harboring BRAF mutations that are very common in cutaneous melanomas.